Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO® (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers

Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO® (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers
Study showed no clinically significant change in blood levels for pitavastatin or protease inhibitor combination darunavir/ritonavir when co-administered

WASHINGTON, July 22, 2012 /PRNewswire via COMTEX/ -- Kowa Pharmaceuticals America, Inc. (Kowa Pharmaceuticals) and Eli Lilly and Company (Lilly) LLY -0.78% today released results from a pharmacokinetic (PK) study exploring potential drug interaction between the cholesterol medication pitavastatin (LIVALO) 4 mg and the protease inhibitor (PI) combination darunavir/ritonavir (Prezista®/Norvir®) 800mg/100mg in healthy volunteers.1 The study, presented at the 19th International AIDS Conference in Washington, DC, found that when co-administered, the blood levels for LIVALO and each of the PIs were not significantly affected.1 In February 2012, the PK data darunavir/ritonavir were added to the LIVALO label.

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.